Oncopeptides
1,498
SEK
-0,27 %
ONCO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 investorer følger denne virksomhed
-0,27%
-30,81%
-31,91%
-44,62%
-72,56%
-75,61%
-74,83%
-98,35%
-95,11%
www.oncopeptides.com/en/investors
Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has drugs in commercialization and several drug candidates under development. Oncopeptide's head office is located in Stockholm.
Omsætning
35,22 mio.
EBIT %
-719,62 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ONCO
Daglig lav / høj pris
1,492 / 1,52
SEK
Markedsværdi
322,35 mio. SEK
Aktieomsætning
19,33 t SEK
Volumen
13 t
Seneste videoer
Finanskalender
Årsrapport
27.02.2025
Delårsrapport
08.05.2025
Generalforsamling
22.05.2025
Delårsrapport
21.08.2025
Delårsrapport
05.11.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
HealthCap VIII L.P. | 12,7 % | 12,9 % |
HealthCap VI L.P. | 6,6 % | 6,7 % |
Avanza Pension | 6,5 % | 6,6 % |
Redmile Group LLC | 6,5 % | 6,6 % |
Hans Edvin Öhman | 4,9 % | 4,9 % |
Nordnet Pensionsförsäkring | 4,5 % | 4,6 % |
Handelsbanken Fonder | 2,5 % | 2,5 % |
Oncopeptides AB | 1,8 % | 0,2 % |
Jakob Lindberg | 0,9 % | 0,9 % |
Johan Zetterstedt | 0,7 % | 0,7 % |
ViserAlle indholdstyper
Oncopeptides invited to present data on PDC platform efficacy in Acute Myeloid Leukemia at the American Society of Hematology meeting
Redeye: Oncopeptides Q3 2024 - Sluggish Growth
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools